Newamsterdam Pharma
NewAmsterdam Pharma Company NV is a Dutch clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative oral therapies for metabolic diseases, prominently featuring obicetrapib, an advanced cholesteryl ester transfer protein (CETP) inhibitor designed for patients with elevated low-density lipoprotein cholesterol (LDL-C) at high risk of cardiovascular disease. The company conducts advanced clinical trials evaluating oral therapeutics intended to reduce cardiovascular morbidity when statin therapies are insufficient. Its core business operations encompass biopharmaceutical clinical research, drug formulation design, regulatory clinical trial execution, and commercial pharmaceutical strategy. As a clinical-stage biopharmaceutical enterprise, the company generates minimal commercial revenue and finances its ongoing operations through public equity offerings and strategic pharmaceutical collaborations. NewAmsterdam Pharma holds a pioneering market position in cardiovascular metabolic therapeutics. The company is headquartered in Naarden, Netherlands, and its common stock trades on the Nasdaq Global Select Market.
10 of the funds FundTelligence covers report a position in Newamsterdam Pharma.
- Legal name
- Newamsterdam Pharma Co NV
- Sector
- Health Care
- Country
- Netherlands
- Funds holding it
- 10
Funds holding Newamsterdam Pharma
- DNB Bioteknologi — DNB · 1.22 % (full portfolio disclosed, September 2026)
- JPM US Small Cap Growth Fund — JPM · 0.69 % (full portfolio disclosed, June 2026)
- SEB Läkemedelsfond — SEB · 0.51 % (full portfolio disclosed, June 2026)
- BNP Health Care Innovators — BNP Paribas · 0.48 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.41 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.4 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 0.12 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 10 funds holding it.